ClinicalTrials.gg
CompletedNCT03029208Updated Oct 20, 2021Results posted

Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-in Incident Dialysis (ASCEND-ID)

A Phase 3 interventional study of Daprodustat and Darbepoetin alfa in Anaemia, sponsored by GlaxoSmithKline. Completed at 111 sites in 15 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2021-10-20.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
312
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 30 studies testing GSK1278863 in Anemia — 1 open to participants now, 1 under way, 1 of them phase 3. GSK1278863 · Anemia.

Enrollment
6th of 30
312 · median 76
Started
2017
with 3 others
Phase 3
9 of 30
1 open now
Registered
18th of 30
by date
Lead sponsor
28 of 30
GlaxoSmithKline

Among the 30 studies testing GSK1278863 in Anemia, this one is the 6th largest by enrollment, is one of 4 that started in 2017, is one of 9 in phase 3, and was the 18th registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

1 of the 30 studies testing GSK1278863 in Anemia is open now. Recruiting first, the newest first:

About GSK1278863

GSK1278863: first FDA approval 2023 (JESDUVROQ). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing GSK1278863 in Anemia, or all of them as a file.
02

Study summary

The purpose of this multi-center study is to evaluate the efficacy and safety of daprodustat in subjects with anemia associated with CKD.

03

Conditions studied

  • Anaemia

Keywords

  • Daprodustat, recombinant human erythropoietin, darbepoetin, anemia, chronic kidney disease, dialysis, ESRD
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 to 99 years of age inclusive.
  • Planning to start chronic dialysis within the next 6 weeks (from the date of the screening visit) OR have started and received dialysis (as specified below) for end-stage renal disease for a maximum of \<=90 days immediately prior to randomization and is not expected to stop dialysis during the duration of the trial: HD >=2 times per week or PD >=4 times per week including incremental schedule; subjects on continuous ambulatory peritoneal dialysis (CAPD) and automated peritoneal dialysis (APD) are eligible.
  • concentration as measured by HemoCue (range inclusive): 8 to 10.5 g/dL (5-6.5 millimoles per liter [mmol/L]) at screening and 8-11.0 g/dL (5 to 6.8 mmol/L) at randomization.
  • Capable of giving signed which includes compliance with the requirements and restrictions listed in the consent form and in this protocol.

Exclusion criteria

Exclusion Criteria:

  • Planned living-related or living-unrelated kidney transplant during the study.
  • Ferritin: \<=100 nanograms per milliliter (ng/mL) (\<=100 micrograms per liter [mcg/L]) at screening or after IV iron supplementation.
  • Transferrin saturation (TSAT): \<=20% at screening or after IV iron supplementation.
  • Vitamin B12 (cobalamin): Below the lower limit of the reference range at screening or after vitamin B12 supplementation.
  • Folate: \<2.0 ng/mL (\<4.5 nanomoles per liter [nmol/L]) at screening.
  • Aplasias: History of bone marrow aplasia or pure red cell aplasia (PRCA).
  • Other causes of anemia: Untreated pernicious anemia, thalassemia major, sickle cell disease, or myelodysplastic syndrome.
  • Gastrointestinal (GI) bleeding: Evidence of actively bleeding gastric, duodenal, or esophageal ulcer disease or GI bleeding \<=10 weeks prior to screening through to randomization (Day 1).
  • Use of any Erythropoiesis-stimulating agent (ESA) treatment within 8 weeks prior to screening except for limited use as part of dialysis initiation. Note : Limited use is defined as no more than 6 weeks of short acting ESA (rhEPO or biosimilars; maximum of 20000 unit total) or long acting ESA (darbepoetin alfa [maximum of 100 mcg total] or methoxy polyethylene glycol-epoetin beta [maximum of 125 mcg total]) received before or after starting dialysis.
  • Myocardial infarction or acute coronary syndrome: \<=10 weeks prior to screening through to randomization (Day 1).
  • Stroke or : \<=10 weeks prior to screening through to randomization (Day 1).
  • Chronic Class IV heart failure, as defined by the (NYHA) functional classification system.
  • Current uncontrolled hypertension as determined by the Investigator that would contraindicate the use of rhEPO.
  • correction using Bazett's (QTcB) (Day 1): QTcB >500 milliseconds (msec), or QTcB >530 msec in subjects with bundle branch block. There is no QTc exclusion for subjects with a predominantly ventricular paced rhythm.
  • Liver disease (any one of the following): 1. (ALT) >2 times (ULN) (screening only). 2. >1.5 times ULN (screening only) (NOTE: Isolated bilirubin >1.5 times ULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%). 3. Current unstable liver or biliary disease per investigator assessment, generally defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice, or cirrhosis. NOTE: Stable chronic liver disease (including asymptomatic gallstones, chronic or C, or Gilbert's syndrome) are acceptable if subject otherwise meets entry criteria.
  • History of within the 2 years prior to screening through to randomization (Day 1), or currently receiving treatment for cancer, or complex kidney cyst (i.e. Bosniak Category II F, III or IV) >3 centimeter (cm). The only exception is localized squamous cell or basal cell carcinoma of the skin that has been definitively treated >=10 weeks prior to screening.
  • History of severe allergic or anaphylactic reactions or to in the product or to darbepoetin alfa.
  • Use of strong Cytochrome P4502C8 (CYP2C8) inhibitors (example gemfibrozil) or strong CYP2C8 inducers (example rifampin/rifampicin).
  • Use of other investigational agent or device prior to screening through to randomization (Day 1). At screening, this exclusion applies to use of the investigational agent within 30 days or within five half-lives (whichever is longer).
  • Any prior treatment with daprodustat for treatment duration of >30 days.
  • Females only: Subject is pregnant [as confirmed by a positive serum human chorionic gonadotropin (hCG) test for females of (FRP) only], subject is breastfeeding, or subject is of reproductive potential and does not agree to follow one of the options in the List of Highly Effective Methods for Avoiding Pregnancy.
  • Any other condition, clinical or laboratory abnormality, or examination finding that the investigator considers would put the subject at unacceptable risk, which may affect study compliance (example intolerance to rhEPO) or prevent understanding of the aims or investigational procedures or possible consequences of the study.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
312 participants (actual)

Study arms

  • Experimental
    Daprodustat treated anemic subjects

    Subjects will receive oral daprodustat once daily.

    Drug: Daprodustat · Drug: Iron therapy

  • Active comparator
    Darbepoetin alfa treated anemic subjects

    Subjects will receive darbepoetin alfa subcutaneously or intravenously.

    Drug: Darbepoetin alfa · Drug: Iron therapy

Interventions

  • Daprodustat will be supplied as film coated tablets for oral administration containing 1, 2, 4, 6, 8, or 10 mg of daprodustat. Doses of 12, 16, and 24 mg of daprodustat will be provided using multiples of these tablet strengths.

  • Darbepoetin alfa will be supplied as prefilled syringes (PFS) for SC/IV injection available in strengths: 20, 30, 40, 60, 80, 100 and 150 mcg.

  • DrugIron therapy

    Iron therapy will be administered if ferritin is \<=100 ng/mL and/or TSAT is \<=20%.

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in Hemoglobin (Hgb) During Evaluation Period (Week 28 to Week 52)

    Blood samples were collected from participants for Hgb measurement. Hgb during the evaluation period was defined as the mean of all available post-randomization Hgb values (on and off-treatment) during the evaluation period (Week 28 to Week 52). For the primary analysis missing post-Baseline Hgb values were imputed using pre-specified multiple imputations. Change from Baseline was defined as the average of post-randomization values during the evaluation period minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date. An analysis of covariance (ANCOVA) model including randomization stratification factors Baseline Hgb and treatment was performed to obtain a point estimate and two-sided 95 percent (%) confidence interval (CI) for the treatment difference (daprodustat-darbepoetin alfa).

    Time frame: Baseline (Pre-dose on Day 1) and evaluation period (Week 28 to Week 52)

Secondary outcomes

  1. Average Monthly Intravenous Iron Dose (Milligrams) From Baseline to Week 52

    Total IV iron dose per participant was calculated from Day 1 to the earliest of (Week 52 visit date, first blood \[red blood cells or whole blood\] transfusion date and treatment stop date plus \[+\] 1 day) which corresponds to the time while the participant was on randomized treatment and before receiving a blood transfusion. Average monthly IV iron dose was calculated by Total IV iron dose divided by (/) (the number of days from Day 1 to the earliest of \[Week 52 visit date, first blood transfusion date and treatment stop date +1\] /30.4375 days). Data for participants until they underwent a red blood cells or whole blood transfusion was included in the analysis.

    Time frame: Baseline (Day 1) to Week 52

  2. Change From Baseline in Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP), Mean Arterial Blood Pressure (MAP) at Week 52

    SBP, DBP and MAP were measured in a semi-supine or seated position in the dialysis chair after at least a 5-minutes of rest. MAP is an average BP in an individual's arteries during a single cardiac cycle. Change from Baseline was calculated as post-dose visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date. This analysis was carried out by using mixed model repeated measures (MMRM) model.

    Time frame: Baseline (Day 1) and Week 52

  3. Change From Baseline in SBP, DBP, MAP at End of Treatment

    SBP, DBP and MAP were measured in a semi-supine or seated position in the dialysis chair after at least a 5-minutes of rest. MAP is an average BP in an individual's arteries during a single cardiac cycle. End of treatment value for the blood pressure parameters were defined as the latest value on or before the last non-zero dose date plus (+) 1 day. Change from Baseline was calculated as post-dose visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date. This analysis was carried out by using ANCOVA model.

    Time frame: Baseline (Day 1) and end of treatment (last on-treatment value until Week 52)

  4. Blood Pressure (BP) Exacerbation Events Rate Per 100 Participant Years

    BP exacerbation event is defined (based on post-dialysis BP) as SBP \>=25 millimeter of mercury (mmHg) increased from Baseline or SBP \>=180 mmHg; or DBP \>=15 mmHg increased from Baseline or DBP \>=110 mmHg. The BP exacerbation events per 100 participant years was estimated using the Negative Binomial Model.

    Time frame: Up to Week 52

  5. Number of Participants With at Least One Blood Pressure Exacerbation Event During Study

    BP exacerbation was defined (based on post-dialysis BP) as: SBP \>=25 mmHg increased from Baseline or SBP \>=180 mmHg; DBP \>=15 mmHg increased from Baseline or DBP \>=110 mmHg. Number of participants with at least one blood pressure exacerbation event is presented.

    Time frame: Up to Week 52

  6. Change From Baseline in Post-randomization Hgb at Week 52

    Blood samples were collected from participants for Hgb measurements. Change from Baseline was calculated as post-dose visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.

    Time frame: Baseline (Day 1) and Week 52

  7. Number of Hgb Responders (Hgb in the Analysis Range of 10 to 11.5 Grams/Deciliter) During Evaluation Period (Week 28 to Week 52)

    Mean Hgb during the evaluation period was defined as the mean of all evaluable Hgb values during the evaluation period (Week 28 to Week 52) including any evaluable unscheduled Hgb values that were taken during this time period. Hgb responders were defined as number of participants with a mean Hgb during the evaluation period that falls within the Hgb analysis range of 10-11.5 g/dL.

    Time frame: Weeks 28 to 52

  8. Percentage of Time for Which Hgb Was Within the Analysis Range (10 to 11.5 g/dL) During Evaluation Period (Week 28 to Week 52): Non-inferiority Analysis

    Percentage of days for which a participant's Hgb was within the analysis range of 10-11.5 g/dL (both inclusive) during the evaluation period (Week 28 to Week 52), including any unscheduled evaluable Hgb values that were taken during this time period was calculated. Percentage of time for which Hgb was within range for a participant was calculated by dividing 'the total number of days that Hgb was within range during Weeks 28 to 52' by 'the total number of days the participant remained on treatment during Weeks 28 to 52'.

    Time frame: Weeks 28 to 52

  9. Percentage of Time for Which Hgb Was Within the Analysis Range (10 to 11.5 g/dL) During Evaluation Period (Week 28 to Week 52): Superiority Analysis

    Percentage of days for which a participant's Hgb was within the analysis range of 10-11.5 g/dL (both inclusive) during the evaluation period (Week 28 to Week 52), including any unscheduled evaluable Hgb values that were taken during this time period was calculated. Percentage of time for which Hgb was within range for a participant was calculated by dividing 'the total number of days that Hgb was within range during Weeks 28 to 52' by 'the total number of days the participant remained on treatment during Weeks 28 to 52'.

    Time frame: Weeks 28 to 52

  10. Number of Participants Permanently Stopping Randomized Treatment Due to Meeting Rescue Criteria

    Number of participants permanently stopping randomized treatment due to meeting rescue criteria has been presented.

    Time frame: Up to Week 52

  11. Change From Baseline in Physical Component Score (PCS) Using Short Form (SF)-36 Health-related Quality of Life (HRQoL) Questionnaire at Weeks 8, 12, 28, 52

    The SF-36 acute version 2 is a 36-item generic quality of life instrument designed to measure a participant's level of performance in the following 8 health domains: physical functioning, role-physical (role limitations caused by physical problems), social functioning, bodily pain, mental health, role-emotional (role limitations caused by emotional problems), vitality and general health. Each domain is scored from 0 (poorer health) to 100 (better health). The PCS is an average score derived from 4 domains (physical functioning, role-physical, bodily pain and general health) representing overall physical health. PCS ranges from 0 to 100; higher scores represent better health. Change from Baseline was calculated as post-dose visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.

    Time frame: Baseline (Day 1), Weeks 8, 12, 28 and 52

  12. Change From Baseline in Mental Component Score (MCS) Using SF-36 HRQoL Questionnaire at Weeks 8, 12, 28, 52

    The SF-36 acute version 2 is a 36-item generic quality of life instrument designed to measure a participant's level of performance in the following 8 health domains: physical functioning, role-physical (role limitations caused by physical problems), social functioning, bodily pain, mental health, role-emotional (role limitations caused by emotional problems), vitality and general health. Each domain is scored from 0 (poorer health) to 100 (better health). MCS is an average score derived from 4 domains (vitality, social functioning, role-emotional and mental health) representing overall mental health. MCS ranges from 0 to 100; higher scores represent better health. Change from Baseline was calculated as post-dose visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.

    Time frame: Baseline (Day 1), Weeks 8, 12, 28 and 52

  13. Change From Baseline in SF-36 HRQoL Scores for Bodily Pain, General Health, Mental Health, Role-Emotional, Role-Physical, Social Functioning at Weeks 8, 12, 28, 52

    The SF-36 acute version 2 is a 36-item generic quality of life instrument designed to measure a participant's level of performance in the following 8 health domains: bodily pain, general health, mental health, role-emotional (role limitations caused by emotional problems), role-physical (role limitations caused by physical problems), social functioning, physical functioning and vitality. Each domain is scored from 0 (poorer health) to 100 (better health). Each domain score ranges from 0 to 100, higher score indicates a better health state and better functioning. Change from Baseline was calculated as post-dose visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.

    Time frame: Baseline (Day 1), Weeks 8, 12, 28 and 52

  14. Change From Baseline in Vitality Scores Using SF-36 HRQoL Questionnaire at Weeks 28, 52

    The SF-36 acute version 2 is a 36-item generic quality of life instrument designed to measure a participant's level of performance in the following 8 health domains: physical functioning, role-physical (role limitations caused by physical problems), social functioning, bodily pain, mental health, role-emotional (role limitations caused by emotional problems), vitality and general health. Each domain is scored from 0 (poorer health) to 100 (better health). Vitality ranges from 0 to 100; higher scores represent better health. Change from Baseline was calculated as post-dose visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.

    Time frame: Baseline (Day 1), Weeks 28 and 52

  15. Change From Baseline in Physical Functioning Domain Scores Using SF-36 HRQoL Questionnaire at Weeks 28, 52

    The SF-36 acute version 2 is a 36-item generic quality of life instrument designed to measure a participant's level of performance in the following 8 health domains: physical functioning, role-physical (role limitations caused by physical problems), social functioning, bodily pain, mental health, role-emotional (role limitations caused by emotional problems), vitality and general health. Each domain is scored from 0 (poorer health) to 100 (better health). Physical functioning ranges from 0 to 100; higher scores represent better health. Change from Baseline was calculated as post-dose visit value minus (-) Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.

    Time frame: Baseline (Day 1), Weeks 28 and 52

  16. Change From Baseline in Health Utility EuroQol 5 Dimensions 5 Level (EQ-5D-5L) Questionnaire Score at Week 52

    EQ-5D-5L consists of 2 concepts-EQ-5D-5L descriptive system and EQ Visual Analogue Scale (EQ-VAS). EQ-5D-5L is self-assessment questionnaire, consisting of 5items covering 5 dimensions (mobility,self care, usual activities, pain/discomfort and anxiety/depression). Each dimension is measured by 5-point Likert scale(no problems, slight problems, moderate problems, severe problems and extreme problems). Responses for 5 dimensions together formed a 5-figure description of health state(e.g.11111 indicates no problems in all 5 dimensions). Each of these 5 figure health states were converted to a single index score by applying country-specific value set formula that attaches weights to dimensions and levels. Range for EQ-5D-5L index score is -0.594 (worst health) to 1 (full health), higher the score better the health status. Change from Baseline was calculated as post-dose visit value-Baseline value. Baseline was latest non-missing pre-dose assessment on or before randomization date.

    Time frame: Baseline (Day 1) and Week 52

  17. Change From Baseline in EQ Visual Analogue Scale (EQ-VAS) at Week 52

    The EQ-5D-5L consists of 2 concepts -EQ-5D-5L descriptive system and EQ-VAS. The EQ-5D-5L is a self-assessment questionnaire, consisting of five items covering five dimensions (mobility, self care, usual activities, pain/discomfort and anxiety/depression). Each dimension is measured by a five-point Likert scale (no problems, slight problems, moderate problems, severe problems, and extreme problems). The range for the EQ-5D-5L index score is 0 to 1 with '0' is worst health and '1' is full health. The EQ VAS records the respondent's self-rated health on a vertical VAS, ranging from 0 to 100, where 0 represents the worst health one can imagine and 100 represents the best health one can imagine. Change from Baseline was calculated as post-dose visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.

    Time frame: Baseline (Day 1) and Week 52

  18. Change From Baseline in Chronic Kidney Disease- Anemia Symptoms Questionnaire (CKD-AQ) at Week 52

    CKD-AQ is 21-item patient reported outcome measure assessing symptoms and symptom impact in participants with anemia associated with CKD. It had 3 domains: 1.Tired/Low Energy/Weak scale consisting of 10 items; 2.Chest Pain/Shortness of Breath scale consisting of 4 items; and 3.Cognitive scale consisting of 3 items. The 4 CKD-AQ single items are: (shortness of breath, no activity), (severity-short breath, resting), (difficulty standing for long time) and (difficulty sleeping). Single-item were recorded based on a 0-100 scoring with 0=worst possible and 100=best possible score. Three domains scores were calculated as average of items in each domain and ranged from 0-100 where 0=worst possible and 100=best possible score. Change from Baseline was calculated as post-dose visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.

    Time frame: Baseline (Day 1) and Week 52

  19. Change From Baseline in Patient Global Impression of Severity (PGI-S)

    The PGI-S is a 1-item questionnaire designed to assess participant's impression of disease severity on a 5-point disease severity scale (0=absent, 1=mild, 2=moderate, 3=severe, or 4=very severe). A higher score indicated worse outcome. Change from Baseline was calculated as post-dose visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.

    Time frame: Baseline (Day 1), Weeks 8, 12, 28 and 52

  20. Plasma Concentration of Daprodustat (GSK1278863) and Its Metabolites GSK2391220 (M2), GSK2506104 (M3), and GSK2531401 (M13)

    Pharmacokinetic samples were collected at pre-dose, 0.5, 1, 2 and 3 hours post-dose on Week 4 or 8 or 12 for pharmacokinetic (PK) analysis of daprodustat (GSK1278863) and its metabolites GSK2391220 (M2), GSK2506104 (M3), and GSK2531401 (M13). GSK2391220, GSK2506104 and GSK2531401 are the metabolites of Daprodustat (GSK1278863). Protocol allowed participants to provide pharmacokinetic samples on Week 4 or 8 or 12. Pharmacokinetic Population comprised of participants for whom a pharmacokinetic sample was obtained and analyzed.

    Time frame: Pre-dose, 0.5, 1, 2 and 3 hours post-dose; each pharmacokinetic sample was taken at Week 4 or 8 or 12

  21. Observed Concentration at Dosing Interval (Ctau) of Daprodustat (GSK1278863) and Its Metabolites GSK2391220 (M2), GSK2506104 (M3), and GSK2531401 (M13)

    Pharmacokinetic samples were collected at pre-dose, 0.5, 1, 2 and 3 hours post-dose on Week 4 or 8 or 12 for pharmacokinetic analysis of daprodustat (GSK1278863) and its metabolites GSK2391220 (M2), GSK2506104 (M3), and GSK2531401 (M13). GSK2391220, GSK2506104 and GSK2531401 are the metabolites of Daprodustat (GSK1278863). Protocol allowed participants to provide pharmacokinetic samples on Week 4 or 8 or 12.

    Time frame: Pre-Dose, 0.5, 1, 2 and 3 hours post-dose; each pharmacokinetic sample was taken at Week 4 or 8 or 12

  22. Maximum Observed Concentration (Cmax) of Daprodustat (GSK1278863) and Its Metabolites GSK2391220 (M2), GSK2506104 (M3), and GSK2531401 (M13)

    Pharmacokinetic samples were collected at pre-dose, 0.5, 1, 2 and 3 hours post-dose on Week 4 or 8 or 12 for pharmacokinetic analysis of daprodustat (GSK1278863) and its metabolites GSK2391220 (M2), GSK2506104 (M3), and GSK2531401 (M13). GSK2391220, GSK2506104 and GSK2531401 are the metabolites of Daprodustat (GSK1278863). Protocol allowed participants to provide pharmacokinetic samples on Week 4 or 8 or 12.

    Time frame: Pre-Dose, 0.5, 1, 2 and 3 hours post-dose; each pharmacokinetic sample was taken at Week 4 or 8 or 12

07

Results

Posted Oct 20, 2021

Participant flow

This was a multicenter study conducted across 14 countries. Participants were randomized to receive either Daprodustat or Darbepoetin alfa.

Participant flow — Overall Study
MilestoneDaprodustatDarbepoetin Alfa
Started157155
Completed155151
Not completed24
Withdrew: Withdrawal by subject23
Withdrew: Lost to follow-up01

Outcome measures

PrimaryMean Change From Baseline in Hemoglobin (Hgb) During Evaluation Period (Week 28 to Week 52)

Blood samples were collected from participants for Hgb measurement. Hgb during the evaluation period was defined as the mean of all available post-randomization Hgb values (on and off-treatment) during the evaluation period (Week 28 to Week 52). For the primary analysis missing post-Baseline Hgb values were imputed using pre-specified multiple imputations. Change from Baseline was defined as the average of post-randomization values during the evaluation period minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date. An analysis of covariance (ANCOVA) model including randomization stratification factors Baseline Hgb and treatment was performed to obtain a point estimate and two-sided 95 percent (%) confidence interval (CI) for the treatment difference (daprodustat-darbepoetin alfa).

Time frame:
Baseline (Pre-dose on Day 1) and evaluation period (Week 28 to Week 52)
Reported as:
Least squares mean · Grams per deciliter
Mean Change From Baseline in Hemoglobin (Hgb) During Evaluation Period (Week 28 to Week 52)
Grams per deciliterDaprodustatDarbepoetin Alfa
Mean Change From Baseline in Hemoglobin (Hgb) During Evaluation Period (Week 28 to Week 52)1.02 ± 0.0861.12 ± 0.085
Statistical analysis
  • Daprodustat vs Darbepoetin Alfa · Least square (ls) mean difference: -0.10 · 95% CI -0.34 to 0.14An ANCOVA model including randomization stratification factors Baseline Hgb and treatment was performed to obtain a point estimate and two-sided 95% CI for the treatment difference (daprodustat-darbepoetin alfa).
SecondaryAverage Monthly Intravenous Iron Dose (Milligrams) From Baseline to Week 52

Total IV iron dose per participant was calculated from Day 1 to the earliest of (Week 52 visit date, first blood \[red blood cells or whole blood\] transfusion date and treatment stop date plus \[+\] 1 day) which corresponds to the time while the participant was on randomized treatment and before receiving a blood transfusion. Average monthly IV iron dose was calculated by Total IV iron dose divided by (/) (the number of days from Day 1 to the earliest of \[Week 52 visit date, first blood transfusion date and treatment stop date +1\] /30.4375 days). Data for participants until they underwent a red blood cells or whole blood transfusion was included in the analysis.

Time frame:
Baseline (Day 1) to Week 52
Reported as:
Least squares mean · Milligram
Average Monthly Intravenous Iron Dose (Milligrams) From Baseline to Week 52
MilligramDaprodustatDarbepoetin Alfa
Average Monthly Intravenous Iron Dose (Milligrams) From Baseline to Week 52144.7 ± 10.90125.3 ± 10.97
Statistical analysis
  • Daprodustat vs Darbepoetin Alfa · ANCOVA · p = 0.8949 · Ls mean difference: 19.4 · 95% CI -11.0 to 49.9An ANCOVA model was used to compare the difference in this average monthly IV iron dose between arms, including factors for Baseline dose, treatment and the randomization stratification factors.
SecondaryChange From Baseline in Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP), Mean Arterial Blood Pressure (MAP) at Week 52

SBP, DBP and MAP were measured in a semi-supine or seated position in the dialysis chair after at least a 5-minutes of rest. MAP is an average BP in an individual's arteries during a single cardiac cycle. Change from Baseline was calculated as post-dose visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date. This analysis was carried out by using mixed model repeated measures (MMRM) model.

Time frame:
Baseline (Day 1) and Week 52
Reported as:
Least squares mean · Millimeter of mercury
Change From Baseline in Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP), Mean Arterial Blood Pressure (MAP) at Week 52
Millimeter of mercuryDaprodustatDarbepoetin Alfa
SBP-3.57 ± 2.063-6.80 ± 2.931
DBP0.21 ± 1.216-4.01 ± 1.650
MAP-0.95 ± 1.364-5.05 ± 1.894
Statistical analysis
  • Daprodustat vs Darbepoetin Alfa · Mixed model repeated measures (MMRM) · p = 0.8168 · Ls mean difference: 3.23 · 95% CI -3.82 to 10.27The difference in change from Baseline in SBP at Week 52 was analyzed with a MMRM approach with an unstructured covariance matrix to compare the difference in LS means between arms.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.9793 · Ls mean difference: 4.21 · 95% CI 0.17 to 8.26The difference in change from Baseline in DBP at Week 52 was analyzed with a MMRM approach with an unstructured covariance matrix to compare the difference in LS means between arms.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.9597 · Ls mean difference: 4.10 · 95% CI -0.51 to 8.70The difference in change from Baseline in MAP at Week 52 was analyzed with a MMRM approach with an unstructured covariance matrix to compare the difference in LS means between arms.
SecondaryChange From Baseline in SBP, DBP, MAP at End of Treatment

SBP, DBP and MAP were measured in a semi-supine or seated position in the dialysis chair after at least a 5-minutes of rest. MAP is an average BP in an individual's arteries during a single cardiac cycle. End of treatment value for the blood pressure parameters were defined as the latest value on or before the last non-zero dose date plus (+) 1 day. Change from Baseline was calculated as post-dose visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date. This analysis was carried out by using ANCOVA model.

Time frame:
Baseline (Day 1) and end of treatment (last on-treatment value until Week 52)
Reported as:
Least squares mean · Millimeter of mercury
Change From Baseline in SBP, DBP, MAP at End of Treatment
Millimeter of mercuryDaprodustatDarbepoetin Alfa
SBP-3.23 ± 1.659-3.14 ± 1.664
DBP0.60 ± 1.016-1.39 ± 1.020
MAP-0.68 ± 1.092-1.97 ± 1.096
Statistical analysis
  • Daprodustat vs Darbepoetin Alfa · ANCOVA · p = 0.4840 · Ls mean difference: -0.09 · 95% CI -4.72 to 4.53The difference in change from Baseline in SBP at the derived end of treatment was analyzed with an ANCOVA model including terms for treatment, prognostic randomization stratification factors.
  • Daprodustat vs Darbepoetin Alfa · ANCOVA · p = 0.9156 · Ls mean difference: 1.99 · 95% CI -0.85 to 4.82The difference in change from Baseline in DBP at the derived end of treatment was analyzed with an ANCOVA model including terms for treatment, prognostic randomization stratification factors.
  • Daprodustat vs Darbepoetin Alfa · ANCOVA · p = 0.7966 · Ls mean difference: 1.29 · 95% CI -1.76 to 4.33The difference in change from Baseline in MAP at the derived end of treatment was analyzed with an ANCOVA model including terms for treatment, prognostic randomization stratification factors.
SecondaryBlood Pressure (BP) Exacerbation Events Rate Per 100 Participant Years

BP exacerbation event is defined (based on post-dialysis BP) as SBP \>=25 millimeter of mercury (mmHg) increased from Baseline or SBP \>=180 mmHg; or DBP \>=15 mmHg increased from Baseline or DBP \>=110 mmHg. The BP exacerbation events per 100 participant years was estimated using the Negative Binomial Model.

Time frame:
Up to Week 52
Reported as:
Number · Events per 100 participant year
Blood Pressure (BP) Exacerbation Events Rate Per 100 Participant Years
Events per 100 participant yearDaprodustatDarbepoetin Alfa
Blood Pressure (BP) Exacerbation Events Rate Per 100 Participant Years352.50 (268.89 to 462.09)350.00 (267.72 to 457.56)
Statistical analysis
  • Daprodustat vs Darbepoetin Alfa · Negative binomial model · p = 0.5174 · Ratio of exacerbation rate: 1.01 · 95% CI 0.73 to 1.39Model estimated exacerbation rates, ratio of model estimated exacerbation rates and CIs were estimated using a negative binomial model for the treatment group comparison.
SecondaryNumber of Participants With at Least One Blood Pressure Exacerbation Event During Study

BP exacerbation was defined (based on post-dialysis BP) as: SBP \>=25 mmHg increased from Baseline or SBP \>=180 mmHg; DBP \>=15 mmHg increased from Baseline or DBP \>=110 mmHg. Number of participants with at least one blood pressure exacerbation event is presented.

Time frame:
Up to Week 52
Reported as:
Count of participants · Participants
Number of Participants With at Least One Blood Pressure Exacerbation Event During Study
ParticipantsDaprodustatDarbepoetin Alfa
Number of Participants With at Least One Blood Pressure Exacerbation Event During Study91100
SecondaryChange From Baseline in Post-randomization Hgb at Week 52

Blood samples were collected from participants for Hgb measurements. Change from Baseline was calculated as post-dose visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.

Time frame:
Baseline (Day 1) and Week 52
Reported as:
Least squares mean · Grams per deciliter
Change From Baseline in Post-randomization Hgb at Week 52
Grams per deciliterDaprodustatDarbepoetin Alfa
Change From Baseline in Post-randomization Hgb at Week 521.17 ± 0.1171.13 ± 0.115
Statistical analysis
  • Daprodustat vs Darbepoetin Alfa · Ls mean difference: 0.04 · 95% CI -0.29 to 0.36The difference in change from Baseline in post-randomization Hgb at Week 52 was analyzed with a MMRM approach with an unstructured covariance matrix to compare the difference in LS means between arms.
SecondaryNumber of Hgb Responders (Hgb in the Analysis Range of 10 to 11.5 Grams/Deciliter) During Evaluation Period (Week 28 to Week 52)

Mean Hgb during the evaluation period was defined as the mean of all evaluable Hgb values during the evaluation period (Week 28 to Week 52) including any evaluable unscheduled Hgb values that were taken during this time period. Hgb responders were defined as number of participants with a mean Hgb during the evaluation period that falls within the Hgb analysis range of 10-11.5 g/dL.

Time frame:
Weeks 28 to 52
Reported as:
Count of participants · Participants
Number of Hgb Responders (Hgb in the Analysis Range of 10 to 11.5 Grams/Deciliter) During Evaluation Period (Week 28 to Week 52)
ParticipantsDaprodustatDarbepoetin Alfa
Number of Hgb Responders (Hgb in the Analysis Range of 10 to 11.5 Grams/Deciliter) During Evaluation Period (Week 28 to Week 52)8687
Statistical analysis
  • Daprodustat vs Darbepoetin Alfa · Cochran-Mantel-Haenszel · p = 0.5411 · Difference in response rate: -0.8 · 95% CI -12.2 to 10.7A Cochran-Mantel-Haenszel (CMH) test adjusted for treatment and randomization stratification factors were used to compare the number of responders between the treatment groups.
SecondaryPercentage of Time for Which Hgb Was Within the Analysis Range (10 to 11.5 g/dL) During Evaluation Period (Week 28 to Week 52): Non-inferiority Analysis

Percentage of days for which a participant's Hgb was within the analysis range of 10-11.5 g/dL (both inclusive) during the evaluation period (Week 28 to Week 52), including any unscheduled evaluable Hgb values that were taken during this time period was calculated. Percentage of time for which Hgb was within range for a participant was calculated by dividing 'the total number of days that Hgb was within range during Weeks 28 to 52' by 'the total number of days the participant remained on treatment during Weeks 28 to 52'.

Time frame:
Weeks 28 to 52
Reported as:
Median · Percentage of days
Percentage of Time for Which Hgb Was Within the Analysis Range (10 to 11.5 g/dL) During Evaluation Period (Week 28 to Week 52): Non-inferiority Analysis
Percentage of daysDaprodustatDarbepoetin Alfa
Percentage of Time for Which Hgb Was Within the Analysis Range (10 to 11.5 g/dL) During Evaluation Period (Week 28 to Week 52): Non-inferiority Analysis57.0 (0.0 to 100.0)54.7 (0.0 to 100.0)
Statistical analysis
  • Daprodustat vs Darbepoetin Alfa · Median difference (final values): 2.05 · 95% CI -4.45 to 11.27Hodges-Lehmann Estimate of Treatment Difference has been reported.
SecondaryPercentage of Time for Which Hgb Was Within the Analysis Range (10 to 11.5 g/dL) During Evaluation Period (Week 28 to Week 52): Superiority Analysis

Percentage of days for which a participant's Hgb was within the analysis range of 10-11.5 g/dL (both inclusive) during the evaluation period (Week 28 to Week 52), including any unscheduled evaluable Hgb values that were taken during this time period was calculated. Percentage of time for which Hgb was within range for a participant was calculated by dividing 'the total number of days that Hgb was within range during Weeks 28 to 52' by 'the total number of days the participant remained on treatment during Weeks 28 to 52'.

Time frame:
Weeks 28 to 52
Reported as:
Median · Percentage of days
Percentage of Time for Which Hgb Was Within the Analysis Range (10 to 11.5 g/dL) During Evaluation Period (Week 28 to Week 52): Superiority Analysis
Percentage of daysDaprodustatDarbepoetin Alfa
Percentage of Time for Which Hgb Was Within the Analysis Range (10 to 11.5 g/dL) During Evaluation Period (Week 28 to Week 52): Superiority Analysis57.0 (0.0 to 100.0)54.7 (0.0 to 100.0)
Statistical analysis
  • Daprodustat vs Darbepoetin Alfa · van Elteren test · p = 0.1538 · Probability: 0.54 · 95% CI 0.46 to 0.61Mann-Whitney estimate (Probability) of the treatment effect has been presented.
SecondaryNumber of Participants Permanently Stopping Randomized Treatment Due to Meeting Rescue Criteria

Number of participants permanently stopping randomized treatment due to meeting rescue criteria has been presented.

Time frame:
Up to Week 52
Reported as:
Count of participants · Participants
Number of Participants Permanently Stopping Randomized Treatment Due to Meeting Rescue Criteria
ParticipantsDaprodustatDarbepoetin Alfa
Number of Participants Permanently Stopping Randomized Treatment Due to Meeting Rescue Criteria55
Statistical analysis
  • Daprodustat vs Darbepoetin Alfa · Wald test · p = 0.5348 · Hazard ratio (hr): 1.06 · 95% CI 0.31 to 3.66Hazard ratio was estimated using a Cox proportional hazard regression model adjusted for treatment group, dialysis type and dialysis start manner.
SecondaryChange From Baseline in Physical Component Score (PCS) Using Short Form (SF)-36 Health-related Quality of Life (HRQoL) Questionnaire at Weeks 8, 12, 28, 52

The SF-36 acute version 2 is a 36-item generic quality of life instrument designed to measure a participant's level of performance in the following 8 health domains: physical functioning, role-physical (role limitations caused by physical problems), social functioning, bodily pain, mental health, role-emotional (role limitations caused by emotional problems), vitality and general health. Each domain is scored from 0 (poorer health) to 100 (better health). The PCS is an average score derived from 4 domains (physical functioning, role-physical, bodily pain and general health) representing overall physical health. PCS ranges from 0 to 100; higher scores represent better health. Change from Baseline was calculated as post-dose visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.

Time frame:
Baseline (Day 1), Weeks 8, 12, 28 and 52
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Physical Component Score (PCS) Using Short Form (SF)-36 Health-related Quality of Life (HRQoL) Questionnaire at Weeks 8, 12, 28, 52
Scores on a scaleDaprodustatDarbepoetin Alfa
Week 8, n=88,860.79 ± 0.6481.18 ± 0.658
Week 12, n=88,881.67 ± 0.6270.54 ± 0.631
Week 28, n=80,740.94 ± 0.6970.45 ± 0.725
Week 52, n=67,650.61 ± 0.7551.93 ± 0.774
Statistical analysis
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.6641 · Ls mean difference: -0.39 · 95% CI -2.22 to 1.44SF-36 HRQoL PCS domain score was analyzed using an MMRM approach with an unstructured covariance matrix to compare the difference in LS means between arms at Week 8.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.1030 · Ls mean difference: 1.13 · 95% CI -0.63 to 2.89SF-36 HRQoL PCS domain score was analyzed using an MMRM approach with an unstructured covariance matrix to compare the difference in LS means between arms at Week 12.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.3157 · Ls mean difference: 0.49 · 95% CI -1.51 to 2.48SF-36 HRQoL PCS domain score was analyzed using an MMRM approach with an unstructured covariance matrix to compare the difference in LS means between arms at Week 28.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.8855 · Ls mean difference: -1.31 · 95% CI -3.46 to 0.84SF-36 HRQoL PCS domain score was analyzed using an MMRM approach with an unstructured covariance matrix to compare the difference in LS means between arms at Week 52.
SecondaryChange From Baseline in Mental Component Score (MCS) Using SF-36 HRQoL Questionnaire at Weeks 8, 12, 28, 52

The SF-36 acute version 2 is a 36-item generic quality of life instrument designed to measure a participant's level of performance in the following 8 health domains: physical functioning, role-physical (role limitations caused by physical problems), social functioning, bodily pain, mental health, role-emotional (role limitations caused by emotional problems), vitality and general health. Each domain is scored from 0 (poorer health) to 100 (better health). MCS is an average score derived from 4 domains (vitality, social functioning, role-emotional and mental health) representing overall mental health. MCS ranges from 0 to 100; higher scores represent better health. Change from Baseline was calculated as post-dose visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.

Time frame:
Baseline (Day 1), Weeks 8, 12, 28 and 52
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Mental Component Score (MCS) Using SF-36 HRQoL Questionnaire at Weeks 8, 12, 28, 52
Scores on a scaleDaprodustatDarbepoetin Alfa
Week 8, n=88,860.10 ± 0.8220.76 ± 0.839
Week 12, n=88,880.08 ± 0.8131.60 ± 0.824
Week 28, n=80,74-0.02 ± 0.9050.30 ± 0.942
Week 52, n=67,65-0.95 ± 1.029-0.72 ± 1.051
Statistical analysis
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.7146 · Ls mean difference: -0.67 · 95% CI -2.99 to 1.66SF-36 HRQoL MCS domain score was analyzed using an MMRM approach with an unstructured covariance matrix to compare the difference in LS means between arms at Week 8.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.9050 · Ls mean difference: -1.53 · 95% CI -3.82 to 0.76SF-36 HRQoL MCS domain score was analyzed using an MMRM approach with an unstructured covariance matrix to compare the difference in LS means between arms at Week 12.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.5950 · Ls mean difference: -0.32 · 95% CI -2.91 to 2.28SF-36 HRQoL MCS domain score was analyzed using an MMRM approach with an unstructured covariance matrix to compare the difference in LS means between arms at Week 28.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.5619 · Ls mean difference: -0.23 · 95% CI -3.17 to 2.70SF-36 HRQoL MCS domain score was analyzed using an MMRM approach with an unstructured covariance matrix to compare the difference in LS means between arms at Week 52.
SecondaryChange From Baseline in SF-36 HRQoL Scores for Bodily Pain, General Health, Mental Health, Role-Emotional, Role-Physical, Social Functioning at Weeks 8, 12, 28, 52

The SF-36 acute version 2 is a 36-item generic quality of life instrument designed to measure a participant's level of performance in the following 8 health domains: bodily pain, general health, mental health, role-emotional (role limitations caused by emotional problems), role-physical (role limitations caused by physical problems), social functioning, physical functioning and vitality. Each domain is scored from 0 (poorer health) to 100 (better health). Each domain score ranges from 0 to 100, higher score indicates a better health state and better functioning. Change from Baseline was calculated as post-dose visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.

Time frame:
Baseline (Day 1), Weeks 8, 12, 28 and 52
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in SF-36 HRQoL Scores for Bodily Pain, General Health, Mental Health, Role-Emotional, Role-Physical, Social Functioning at Weeks 8, 12, 28, 52
Scores on a scaleDaprodustatDarbepoetin Alfa
Bodily pain: Week 8, n=88,86-0.41 ± 0.833-0.55 ± 0.843
Bodily pain: Week 12, n=88,88-0.13 ± 0.892-0.06 ± 0.895
Bodily pain: Week 28, n=80,741.08 ± 0.941-1.26 ± 0.976
Bodily pain: Week 52, n=67,65-2.00 ± 1.0840.61 ± 1.109
General health: Week 8, n=88,860.80 ± 0.6620.75 ± 0.674
General health: Week 12, n=88,880.87 ± 0.6510.59 ± 0.658
General health: Week 28, n=80,740.63 ± 0.6930.37 ± 0.720
General health: Week 52, n=67,650.40 ± 0.8230.58 ± 0.841
Mental health: Week 8, n=88,86-0.90 ± 0.8250.25 ± 0.841
Mental health: Week 12, n=88,880.01 ± 0.7071.42 ± 0.712
Mental health: Week 28, n=80,74-0.69 ± 0.866-0.21 ± 0.902
Mental health: Week 52, n=67,65-0.53 ± 0.994-0.27 ± 1.013
Role-emotional: Week 8, n=88,860.83 ± 0.8800.50 ± 0.896
Role-emotional: Week 12, n=88,880.55 ± 0.934-0.07 ± 0.946
Role-emotional: Week 28, n=80,740.91 ± 0.9290.39 ± 0.964
Role-emotional: Week 52, n=67,65-1.60 ± 1.193-0.11 ± 1.216
Role-physical: Week 8, n=88,861.34 ± 0.8062.64 ± 0.818
Role-physical: Week 12, n=88,882.39 ± 0.7121.69 ± 0.716
Role-physical: Week 28, n=80,740.62 ± 0.7991.49 ± 0.829
Role-physical: Week 52, n=67,651.49 ± 0.8952.22 ± 0.913
Social functioning: Week 8, n=88,860.52 ± 0.9291.55 ± 0.947
Social functioning: Week 12, n=88,880.98 ± 0.7742.15 ± 0.783
Social functioning: Week 28, n=80,741.03 ± 0.9430.95 ± 0.980
Social functioning: Week 52, n=67,650.39 ± 1.085-0.33 ± 1.105
Statistical analysis
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.4523 · Ls mean difference: 0.14 · 95% CI -2.21 to 2.49SF-36 HRQoL bodily pain domain score was analyzed using an MMRM approach with an unstructured covariance matrix to compare the difference in LS means between arms at Week 8.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.5222 · Ls mean difference: -0.07 · 95% CI -2.57 to 2.43SF-36 HRQoL bodily pain domain score was analyzed using an MMRM approach with an unstructured covariance matrix to compare the difference in LS means between arms at Week 12.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.0440 · Ls mean difference: 2.33 · 95% CI -0.35 to 5.02SF-36 HRQoL bodily pain domain score was analyzed using an MMRM approach with an unstructured covariance matrix to compare the difference in LS means between arms at Week 28.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.9523 · Ls mean difference: -2.61 · 95% CI -5.68 to 0.46SF-36 HRQoL bodily pain domain score was analyzed using an MMRM approach with an unstructured covariance matrix to compare the difference in LS means between arms at Week 52.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.4811 · Ls mean difference: 0.05 · 95% CI -1.82 to 1.91SF-36 HRQoL general health domain score was analyzed using an MMRM approach with an unstructured covariance matrix to compare the difference in LS means between arms at Week 8.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.3834 · Ls mean difference: 0.28 · 95% CI -1.56 to 2.11SF-36 HRQoL general health domain score was analyzed using an MMRM approach with an unstructured covariance matrix to compare the difference in LS means between arms at Week 12.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.3983 · Ls mean difference: 0.26 · 95% CI -1.72 to 2.24SF-36 HRQoL general health domain score was analyzed using an MMRM approach with an unstructured covariance matrix to compare the difference in LS means between arms at Week 28.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.5617 · Ls mean difference: -0.18 · 95% CI -2.51 to 2.15SF-36 HRQoL general health domain score was analyzed using an MMRM approach with an unstructured covariance matrix to compare the difference in LS means between arms at Week 52.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.8336 · Ls mean difference: -1.15 · 95% CI -3.48 to 1.18SF-36 HRQoL mental health domain score was analyzed using an MMRM approach with an unstructured covariance matrix to compare the difference in LS means between arms at Week 8.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.9188 · Ls mean difference: -1.41 · 95% CI -3.40 to 0.57SF-36 HRQoL mental health domain score was analyzed using an MMRM approach with an unstructured covariance matrix to compare the difference in LS means between arms at Week 12.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.6495 · Ls mean difference: -0.48 · 95% CI -2.96 to 1.99SF-36 HRQoL mental health domain score was analyzed using an MMRM approach with an unstructured covariance matrix to compare the difference in LS means between arms at Week 28.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.5737 · Ls mean difference: -0.27 · 95% CI -3.09 to 2.56SF-36 HRQoL mental health domain score was analyzed using an MMRM approach with an unstructured covariance matrix to compare the difference in LS means between arms at Week 52.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.3963 · Ls mean difference: 0.33 · 95% CI -2.15 to 2.82SF-36 HRQoL role-emotional domain score was analyzed using an MMRM approach with an unstructured covariance matrix to compare the difference in LS means between arms at Week 8.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.3220 · Ls mean difference: 0.62 · 95% CI -2.01 to 3.25SF-36 HRQoL role-emotional domain score was analyzed using an MMRM approach with an unstructured covariance matrix to compare the difference in LS means between arms at Week 12.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.3485 · Ls mean difference: 0.53 · 95% CI -2.13 to 3.18SF-36 HRQoL role-emotional domain score was analyzed using an MMRM approach with an unstructured covariance matrix to compare the difference in LS means between arms at Week 28.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.8064 · Ls mean difference: -1.49 · 95% CI -4.87 to 1.90SF-36 HRQoL role-emotional domain score was analyzed using an MMRM approach with an unstructured covariance matrix to compare the difference in LS means between arms at Week 52.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.8687 · Ls mean difference: -1.29 · 95% CI -3.57 to 0.98SF-36 HRQoL role-physical domain score was analyzed using an MMRM approach with an unstructured covariance matrix to compare the difference in LS means between arms at Week 8.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.2435 · Ls mean difference: 0.71 · 95% CI -1.29 to 2.70SF-36 HRQoL role-physical domain score was analyzed using an MMRM approach with an unstructured covariance matrix to compare the difference in LS means between arms at Week 12.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.7747 · Ls mean difference: -0.87 · 95% CI -3.15 to 1.41SF-36 HRQoL role-physical domain score was analyzed using an MMRM approach with an unstructured covariance matrix to compare the difference in LS means between arms at Week 28.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.7141 · Ls mean difference: -0.73 · 95% CI -3.26 to 1.81SF-36 HRQoL role-physical domain score was analyzed using an MMRM approach with an unstructured covariance matrix to compare the difference in LS means between arms at Week 52.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.7803 · Ls mean difference: -1.03 · 95% CI -3.65 to 1.59SF-36 HRQoL social functioning domain score was analyzed using an MMRM approach with an unstructured covariance matrix to compare the difference in LS means between arms at Week 8.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.8556 · Ls mean difference: -1.18 · 95% CI -3.35 to 1.00SF-36 HRQoL social functioning domain score was analyzed using an MMRM approach with an unstructured covariance matrix to compare the difference in LS means between arms at Week 12.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.4763 · Ls mean difference: 0.08 · 95% CI -2.61 to 2.77SF-36 HRQoL social functioning domain score was analyzed using an MMRM approach with an unstructured covariance matrix to compare the difference in LS means between arms at Week 28.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.3208 · Ls mean difference: 0.73 · 95% CI -2.35 to 3.80SF-36 HRQoL social functioning domain score was analyzed using an MMRM approach with an unstructured covariance matrix to compare the difference in LS means between arms at Week 52.
SecondaryChange From Baseline in Vitality Scores Using SF-36 HRQoL Questionnaire at Weeks 28, 52

The SF-36 acute version 2 is a 36-item generic quality of life instrument designed to measure a participant's level of performance in the following 8 health domains: physical functioning, role-physical (role limitations caused by physical problems), social functioning, bodily pain, mental health, role-emotional (role limitations caused by emotional problems), vitality and general health. Each domain is scored from 0 (poorer health) to 100 (better health). Vitality ranges from 0 to 100; higher scores represent better health. Change from Baseline was calculated as post-dose visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.

Time frame:
Baseline (Day 1), Weeks 28 and 52
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Vitality Scores Using SF-36 HRQoL Questionnaire at Weeks 28, 52
Scores on a scaleDaprodustatDarbepoetin Alfa
Week 28, n=80,74-0.08 ± 0.8660.95 ± 0.902
Week 52, n=67,650.16 ± 0.9071.61 ± 0.925
Statistical analysis
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.7910 · Ls mean difference: -1.02 · 95% CI -3.50 to 1.46SF-36 HRQoL vitality domain score was analyzed using an MMRM approach with an unstructured covariance matrix to compare the difference in LS means between arms at Week 28.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.8648 · Ls mean difference: -1.45 · 95% CI -4.03 to 1.14SF-36 HRQoL vitality domain score was analyzed using an MMRM approach with an unstructured covariance matrix to compare the difference in LS means between arms at Week 52.
SecondaryChange From Baseline in Physical Functioning Domain Scores Using SF-36 HRQoL Questionnaire at Weeks 28, 52

The SF-36 acute version 2 is a 36-item generic quality of life instrument designed to measure a participant's level of performance in the following 8 health domains: physical functioning, role-physical (role limitations caused by physical problems), social functioning, bodily pain, mental health, role-emotional (role limitations caused by emotional problems), vitality and general health. Each domain is scored from 0 (poorer health) to 100 (better health). Physical functioning ranges from 0 to 100; higher scores represent better health. Change from Baseline was calculated as post-dose visit value minus (-) Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.

Time frame:
Baseline (Day 1), Weeks 28 and 52
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Physical Functioning Domain Scores Using SF-36 HRQoL Questionnaire at Weeks 28, 52
Scores on a scaleDaprodustatDarbepoetin Alfa
Week 28, n=80,740.55 ± 0.8630.83 ± 0.898
Week 52, n=67,650.14 ± 0.9471.58 ± 0.973
Statistical analysis
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.5879 · Ls mean difference: -0.28 · 95% CI -2.75 to 2.19SF-36 HRQoL physical functioning domain score was analyzed using an MMRM approach with an unstructured covariance matrix to compare the difference in LS means between arms at Week 28.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.8525 · Ls mean difference: -1.43 · 95% CI -4.12 to 1.26SF-36 HRQoL physical functioning domain scor was analyzed using an MMRM approach with an unstructured covariance matrix to compare the difference in LS means between arms at Week 52.
SecondaryChange From Baseline in Health Utility EuroQol 5 Dimensions 5 Level (EQ-5D-5L) Questionnaire Score at Week 52

EQ-5D-5L consists of 2 concepts-EQ-5D-5L descriptive system and EQ Visual Analogue Scale (EQ-VAS). EQ-5D-5L is self-assessment questionnaire, consisting of 5items covering 5 dimensions (mobility,self care, usual activities, pain/discomfort and anxiety/depression). Each dimension is measured by 5-point Likert scale(no problems, slight problems, moderate problems, severe problems and extreme problems). Responses for 5 dimensions together formed a 5-figure description of health state(e.g.11111 indicates no problems in all 5 dimensions). Each of these 5 figure health states were converted to a single index score by applying country-specific value set formula that attaches weights to dimensions and levels. Range for EQ-5D-5L index score is -0.594 (worst health) to 1 (full health), higher the score better the health status. Change from Baseline was calculated as post-dose visit value-Baseline value. Baseline was latest non-missing pre-dose assessment on or before randomization date.

Time frame:
Baseline (Day 1) and Week 52
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Health Utility EuroQol 5 Dimensions 5 Level (EQ-5D-5L) Questionnaire Score at Week 52
Scores on a scaleDaprodustatDarbepoetin Alfa
Change From Baseline in Health Utility EuroQol 5 Dimensions 5 Level (EQ-5D-5L) Questionnaire Score at Week 520.00 ± 0.041-0.03 ± 0.040
Statistical analysis
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.3154 · Ls mean difference: 0.03 · 95% CI -0.09 to 0.14MMRM model was fitted from Baseline up to Week 52 with factors for treatment, time, dialysis type, dialysis start manner, Baseline value and Baseline value by time and treatment by time interactions.
SecondaryChange From Baseline in EQ Visual Analogue Scale (EQ-VAS) at Week 52

The EQ-5D-5L consists of 2 concepts -EQ-5D-5L descriptive system and EQ-VAS. The EQ-5D-5L is a self-assessment questionnaire, consisting of five items covering five dimensions (mobility, self care, usual activities, pain/discomfort and anxiety/depression). Each dimension is measured by a five-point Likert scale (no problems, slight problems, moderate problems, severe problems, and extreme problems). The range for the EQ-5D-5L index score is 0 to 1 with '0' is worst health and '1' is full health. The EQ VAS records the respondent's self-rated health on a vertical VAS, ranging from 0 to 100, where 0 represents the worst health one can imagine and 100 represents the best health one can imagine. Change from Baseline was calculated as post-dose visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.

Time frame:
Baseline (Day 1) and Week 52
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in EQ Visual Analogue Scale (EQ-VAS) at Week 52
Scores on a scaleDaprodustatDarbepoetin Alfa
Change From Baseline in EQ Visual Analogue Scale (EQ-VAS) at Week 523.4 ± 3.276.8 ± 3.28
Statistical analysis
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.7651 · Ls mean difference: -3.4 · 95% CI -12.7 to 5.9MMRM model was fitted from Baseline up to Week 52 with factors for treatment, time, dialysis type, dialysis start manner, Baseline value and Baseline value by time and treatment by time interactions.
SecondaryChange From Baseline in Chronic Kidney Disease- Anemia Symptoms Questionnaire (CKD-AQ) at Week 52

CKD-AQ is 21-item patient reported outcome measure assessing symptoms and symptom impact in participants with anemia associated with CKD. It had 3 domains: 1.Tired/Low Energy/Weak scale consisting of 10 items; 2.Chest Pain/Shortness of Breath scale consisting of 4 items; and 3.Cognitive scale consisting of 3 items. The 4 CKD-AQ single items are: (shortness of breath, no activity), (severity-short breath, resting), (difficulty standing for long time) and (difficulty sleeping). Single-item were recorded based on a 0-100 scoring with 0=worst possible and 100=best possible score. Three domains scores were calculated as average of items in each domain and ranged from 0-100 where 0=worst possible and 100=best possible score. Change from Baseline was calculated as post-dose visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.

Time frame:
Baseline (Day 1) and Week 52
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Chronic Kidney Disease- Anemia Symptoms Questionnaire (CKD-AQ) at Week 52
Scores on a scaleDaprodustatDarbepoetin Alfa
Tired/Low energy/Weak domain-2.36 ± 2.0074.07 ± 1.990
Chest pain/Shortness of breath domain-1.83 ± 1.5932.28 ± 1.557
Cognitive domain-4.17 ± 1.8932.43 ± 1.852
Shortness of breath, no activity-1.90 ± 1.8611.14 ± 1.826
Severity-short breath, Resting-4.16 ± 1.8690.12 ± 1.836
Difficulty standing for long time-2.00 ± 2.8123.30 ± 2.754
Difficulty sleeping-5.27 ± 2.6671.26 ± 2.611
Statistical analysis
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.9875 · Ls mean difference: -6.43 · 95% CI -12.05 to -0.82Tired/Low energy/Weak domain: MMRM model was fitted from Baseline up to Week 52 with factors for treatment, time, dialysis type, dialysis start manner, Baseline value and Baseline value by time and treatment by time interactions.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.9663 · Ls mean difference: -4.11 · 95% CI -8.52 to 0.30Chest pain/Shortness of breath domain: MMRM model was fitted from Baseline up to Week 52 with factors for treatment, time, dialysis type, dialysis start manner, Baseline value and Baseline value by time and treatment by time interactions.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.9930 · Ls mean difference: -6.60 · 95% CI -11.84 to -1.35Cognitive domain: MMRM model was fitted from Baseline up to Week 52 with factors for treatment, time, dialysis type, dialysis start manner, Baseline value and Baseline value by time and treatment by time interactions.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.8765 · Ls mean difference: -3.03 · 95% CI -8.19 to 2.12Shortness of breath, no activity: MMRM model was fitted from Baseline up to Week 52 with factors for treatment, time, dialysis type, dialysis start manner, Baseline value and Baseline value by time and treatment by time interactions.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.9464 · Ls mean difference: -4.27 · 95% CI -9.48 to 0.94Severity-short breath, Resting: MMRM model was fitted from Baseline up to Week 52 with factors for treatment, time, dialysis type, dialysis start manner, Baseline value and Baseline value by time and treatment by time interactions.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.9101 · Ls mean difference: -5.31 · 95% CI -13.09 to 2.47Difficulty standing for long time: MMRM model was fitted from Baseline up to Week 52 with factors for treatment, time, dialysis type, dialysis start manner, Baseline value and Baseline value by time and treatment by time interactions.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.9586 · Ls mean difference: -6.52 · 95% CI -13.90 to 0.86Difficulty sleeping: MMRM model was fitted from Baseline up to Week 52 with factors for treatment, time, dialysis type, dialysis start manner, Baseline value and Baseline value by time and treatment by time interactions.
SecondaryChange From Baseline in Patient Global Impression of Severity (PGI-S)

The PGI-S is a 1-item questionnaire designed to assess participant's impression of disease severity on a 5-point disease severity scale (0=absent, 1=mild, 2=moderate, 3=severe, or 4=very severe). A higher score indicated worse outcome. Change from Baseline was calculated as post-dose visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.

Time frame:
Baseline (Day 1), Weeks 8, 12, 28 and 52
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Patient Global Impression of Severity (PGI-S)
Scores on a scaleDaprodustatDarbepoetin Alfa
Week 8, n=100,1000.16 ± 0.091-0.11 ± 0.092
Week 12, n=100,1030.02 ± 0.077-0.03 ± 0.077
Week 28, n=92,850.09 ± 0.086-0.07 ± 0.089
Week 52, n=75,770.22 ± 0.1060.04 ± 0.105
Statistical analysis
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.9810 · Ls mean difference: 0.27 · 95% CI 0.02 to 0.53MMRM model was fitted from Baseline up to Week 8 with factors for treatment, time, dialysis type, dialysis start manner, Baseline value and Baseline value by time and treatment by time interactions.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.6743 · Ls mean difference: 0.05 · 95% CI -0.17 to 0.26MMRM model was fitted from Baseline up to Week 12 with factors for treatment, time, dialysis type, dialysis start manner, Baseline value and Baseline value by time and treatment by time interactions.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.8997 · Ls mean difference: 0.16 · 95% CI -0.09 to 0.40MMRM model was fitted from Baseline up to Week 28 with factors for treatment, time, dialysis type, dialysis start manner, Baseline value and Baseline value by time and treatment by time interactions.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.8835 · Ls mean difference: 0.18 · 95% CI -0.12 to 0.47MMRM model was fitted from Baseline up to Week 52 with factors for treatment, time, dialysis type, dialysis start manner, Baseline value and Baseline value by time and treatment by time interactions.
SecondaryPlasma Concentration of Daprodustat (GSK1278863) and Its Metabolites GSK2391220 (M2), GSK2506104 (M3), and GSK2531401 (M13)

Pharmacokinetic samples were collected at pre-dose, 0.5, 1, 2 and 3 hours post-dose on Week 4 or 8 or 12 for pharmacokinetic (PK) analysis of daprodustat (GSK1278863) and its metabolites GSK2391220 (M2), GSK2506104 (M3), and GSK2531401 (M13). GSK2391220, GSK2506104 and GSK2531401 are the metabolites of Daprodustat (GSK1278863). Protocol allowed participants to provide pharmacokinetic samples on Week 4 or 8 or 12. Pharmacokinetic Population comprised of participants for whom a pharmacokinetic sample was obtained and analyzed.

Time frame:
Pre-dose, 0.5, 1, 2 and 3 hours post-dose; each pharmacokinetic sample was taken at Week 4 or 8 or 12
Reported as:
Mean · Nanogram per milliliter
Plasma Concentration of Daprodustat (GSK1278863) and Its Metabolites GSK2391220 (M2), GSK2506104 (M3), and GSK2531401 (M13)
Nanogram per milliliterDaprodustat 1 mgDaprodustat 2 mgDaprodustat 4 mgDaprodustat 6 mgDaprodustat 8 mgDaprodustat 10 mgDaprodustat 12 mgDaprodustat 16 mgDaprodustat 24 mg
Daprodustat: Pre-Dose, n=19,26,20,18,1,1,0,0,02.118 ± 5.00301.015 ± 3.14510.5787 ± 1.57182.867 ± 6.61420.1030 ± NA0.1090 ± NA———
Daprodustat: 0.5 hour, n=19,26,20,18,0,1,0,0,05.675 ± 8.49984.664 ± 8.750810.27 ± 20.42512.58 ± 23.742—145.0 ± NA———
Daprodustat: 1 hour, n=19,26,20,18,1,1,0,0,012.34 ± 13.43521.45 ± 42.16036.78 ± 62.49745.48 ± 48.7650.9120 ± NA79.60 ± NA———
Daprodustat: 2 hours, n=19,26,20,18,1,1,0,0,012.74 ± 9.901920.36 ± 22.21054.68 ± 80.28455.62 ± 51.47132.00 ± NA27.60 ± NA———
Daprodustat: 3 hours, n=19,26,19,18,1,1,0,0,07.719 ± 5.914415.58 ± 13.69443.34 ± 66.29556.49 ± 74.35725.30 ± NA11.00 ± NA———
GSK2391220: Pre-Dose, n=19,26,20,18,1,1,0,0,00.7106 ± 0.640282.124 ± 2.87212.087 ± 2.13713.560 ± 4.22554.450 ± NA6.560 ± NA———
GSK2391220: 0.5 hour, n=19,25,20,18,1,1,0,0,00.7602 ± 0.679501.807 ± 2.20071.822 ± 2.13552.410 ± 2.82433.950 ± NA6.740 ± NA———
GSK2391220: 1 hour, n=18,26,20,18,1,1,0,0,01.123 ± 0.769201.752 ± 1.85891.965 ± 2.28303.140 ± 2.48563.900 ± NA10.00 ± NA———
GSK2391220: 2 hours, n=19,26,20,18,1,1,0,0,01.745 ± 1.31602.969 ± 2.46594.008 ± 4.45226.336 ± 4.37234.700 ± NA16.20 ± NA———
GSK2391220: 3 hours, n=19,26,19,18,1,1,0,0,01.911 ± 1.22743.535 ± 2.72035.553 ± 6.51579.372 ± 6.64526.090 ± NA16.60 ± NA———
GSK2506104: Pre-Dose, n=19,26,20,18,1,1,0,0,01.270 ± 0.960713.508 ± 4.20663.879 ± 3.42075.921 ± 5.89818.710 ± NA9.500 ± NA———
GSK2506104: 0.5 hour, n=19,26,20,18,1,1,0,0,01.197 ± 0.851042.788 ± 2.98933.315 ± 3.42494.015 ± 3.73857.740 ± NA8.110 ± NA———
GSK2506104: 1 hour, n=19,26,20,18,1,1,0,0,01.364 ± 0.962922.610 ± 2.47613.268 ± 3.48084.333 ± 3.05057.460 ± NA12.40 ± NA———
GSK2506104: 2 hours, n=19,26,20,18,1,1,0,0,01.966 ± 1.34403.583 ± 2.84274.989 ± 5.21097.130 ± 4.51058.930 ± NA19.60 ± NA———
GSK2506104: 3 hours, n=19,26,19,18,1,1,0,0,02.190 ± 1.38984.145 ± 3.17576.503 ± 7.51309.942 ± 7.061610.10 ± NA22.00 ± NA———
GSK2531401: Pre-Dose, n=19,26,20,18,1,1,0,0,01.642 ± 1.48362.729 ± 1.89343.750 ± 3.80065.111 ± 4.06325.660 ± NA7.760 ± NA———
GSK2531401: 0.5 hour, n=19,26,20,18,1,1,0,0,01.427 ± 1.28702.170 ± 1.66213.263 ± 3.87373.800 ± 2.87224.960 ± NA6.460 ± NA———
GSK2531401: 1 hour, n=19,26,20,18,1,1,0,0,01.399 ± 1.45951.979 ± 1.63163.146 ± 4.03343.776 ± 3.44114.810 ± NA6.630 ± NA———
GSK2531401: 2 hours, n=19,26,20,18,1,1,0,0,01.690 ± 1.63092.338 ± 2.14673.711 ± 5.02234.892 ± 4.78775.190 ± NA8.290 ± NA———
GSK2531401: 3 hours, n=19,26,19,18,1,1,0,0,01.847 ± 1.73762.734 ± 2.68464.715 ± 7.27886.631 ± 7.10495.760 ± NA10.20 ± NA———
SecondaryObserved Concentration at Dosing Interval (Ctau) of Daprodustat (GSK1278863) and Its Metabolites GSK2391220 (M2), GSK2506104 (M3), and GSK2531401 (M13)

Pharmacokinetic samples were collected at pre-dose, 0.5, 1, 2 and 3 hours post-dose on Week 4 or 8 or 12 for pharmacokinetic analysis of daprodustat (GSK1278863) and its metabolites GSK2391220 (M2), GSK2506104 (M3), and GSK2531401 (M13). GSK2391220, GSK2506104 and GSK2531401 are the metabolites of Daprodustat (GSK1278863). Protocol allowed participants to provide pharmacokinetic samples on Week 4 or 8 or 12.

Time frame:
Pre-Dose, 0.5, 1, 2 and 3 hours post-dose; each pharmacokinetic sample was taken at Week 4 or 8 or 12
Reported as:
Mean · Nanogram per milliliter
Observed Concentration at Dosing Interval (Ctau) of Daprodustat (GSK1278863) and Its Metabolites GSK2391220 (M2), GSK2506104 (M3), and GSK2531401 (M13)
Nanogram per milliliterDaprodustat 1 mgDaprodustat 2 mgDaprodustat 4 mgDaprodustat 6 mgDaprodustat 8 mgDaprodustat 10 mgDaprodustat 12 mgDaprodustat 16 mgDaprodustat 24 mg
Daprodustat2.118 ± 5.00301.015 ± 3.14510.5787 ± 1.57182.867 ± 6.61420.1030 ± NA0.1090 ± NA———
GSK23912200.7106 ± 0.640282.124 ± 2.87212.087 ± 2.13713.560 ± 4.22554.450 ± NA6.560 ± NA———
GSK25061041.270 ± 0.960713.508 ± 4.20663.879 ± 3.42075.921 ± 5.89818.710 ± NA9.500 ± NA———
GSK25314011.642 ± 1.48362.729 ± 1.89343.750 ± 3.80065.111 ± 4.06325.660 ± NA7.760 ± NA———
SecondaryMaximum Observed Concentration (Cmax) of Daprodustat (GSK1278863) and Its Metabolites GSK2391220 (M2), GSK2506104 (M3), and GSK2531401 (M13)

Pharmacokinetic samples were collected at pre-dose, 0.5, 1, 2 and 3 hours post-dose on Week 4 or 8 or 12 for pharmacokinetic analysis of daprodustat (GSK1278863) and its metabolites GSK2391220 (M2), GSK2506104 (M3), and GSK2531401 (M13). GSK2391220, GSK2506104 and GSK2531401 are the metabolites of Daprodustat (GSK1278863). Protocol allowed participants to provide pharmacokinetic samples on Week 4 or 8 or 12.

Time frame:
Pre-Dose, 0.5, 1, 2 and 3 hours post-dose; each pharmacokinetic sample was taken at Week 4 or 8 or 12
Reported as:
Mean · Nanogram per milliliter
Maximum Observed Concentration (Cmax) of Daprodustat (GSK1278863) and Its Metabolites GSK2391220 (M2), GSK2506104 (M3), and GSK2531401 (M13)
Nanogram per milliliterDaprodustat 1 mgDaprodustat 2 mgDaprodustat 4 mgDaprodustat 6 mgDaprodustat 8 mgDaprodustat 10 mgDaprodustat 12 mgDaprodustat 16 mgDaprodustat 24 mg
Daprodustat21.74 ± 10.99832.29 ± 40.16676.92 ± 81.867100.2 ± 74.08632.00 ± NA145.0 ± NA———
GSK23912202.160 ± 1.25964.139 ± 3.35615.780 ± 6.284010.36 ± 6.33776.090 ± NA16.60 ± NA———
GSK25061042.477 ± 1.36255.212 ± 4.55627.075 ± 7.131311.60 ± 6.873110.10 ± NA22.00 ± NA———
GSK25314012.283 ± 1.82103.565 ± 2.60915.328 ± 6.90347.836 ± 6.61995.760 ± NA10.20 ± NA———

Adverse events

Collected over All-cause mortality, treatment emergent non-serious adverse events and serious adverse events were collected up to follow-up visit (Week 58). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Daprodustat17/157 (10.8%)52/157 (33.1%)76/157 (48.4%)
Darbepoetin Alfa12/155 (7.7%)51/155 (32.9%)74/155 (47.7%)
Most frequent serious events
Showing 10 of 129
Most frequent serious events
EventDaprodustatDarbepoetin Alfa
PneumoniaInfections and infestations4/1577/155
Fluid overloadMetabolism and nutrition disorders5/1573/155
Arteriovenous fistula thrombosisInjury, poisoning and procedural complications1/1574/155
Device malfunctionProduct Issues4/1570/155
PeritonitisInfections and infestations1/1573/155
SepsisInfections and infestations0/1573/155
HypoglycaemiaMetabolism and nutrition disorders0/1573/155
Acute myocardial infarctionCardiac disorders0/1573/155
Abdominal painGastrointestinal disorders0/1573/155
Post procedural infectionInfections and infestations3/1570/155
Most frequent other events
Showing 10 of 13
Most frequent other events
EventDaprodustatDarbepoetin Alfa
HypertensionVascular disorders27/15724/155
Dialysis hypotensionVascular disorders21/15715/155
DiarrhoeaGastrointestinal disorders14/15710/155
HeadacheNervous system disorders12/1579/155
Upper respiratory tract infectionInfections and infestations7/15711/155
VomitingGastrointestinal disorders11/1575/155
HypotensionVascular disorders7/1579/155
NasopharyngitisInfections and infestations7/1579/155
Muscle spasmsMusculoskeletal and connective tissue disorders7/1579/155
Fluid overloadMetabolism and nutrition disorders9/1576/155

Baseline characteristics

Age, Continuous
Age, Continuous(Years)DaprodustatDarbepoetin AlfaTotal
Mean53.7 ± 14.3155.8 ± 15.7054.7 ± 15.03
Sex: Female, Male
Sex: Female, Male(Participants)DaprodustatDarbepoetin AlfaTotal
Female6157118
Male9698194
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)DaprodustatDarbepoetin AlfaTotal
American Indian (AI) or Alaskan Native (AN)527
Asian: Central/South Asian Heritage7613
Asian: East Asian Heritage81624
Asian: South East Asian Heritage11920
Black or African American161329
White: Arabic/North African Heritage101
White: White/Caucasian/European Heritage109107216
Mixed race: AI or AN and White022
08

Study locations

111 sites
  • GSK Investigational Site
    Anaheim, California 92801, United States
  • GSK Investigational Site
    Cerritos, California 90703, United States
  • GSK Investigational Site
    Escondido, California 92025, United States
  • GSK Investigational Site
    Glendale, California 91204, United States
  • GSK Investigational Site
    La Palma, California 90623, United States
  • GSK Investigational Site
    Los Angeles, California 90022, United States
  • GSK Investigational Site
    Los Angeles, California 90095, United States
  • GSK Investigational Site
    Lynwood, California 90262, United States
  • GSK Investigational Site
    Sacramento, California 95825, United States
  • GSK Investigational Site
    Whittier, California 90603, United States
  • GSK Investigational Site
    Middlebury, Connecticut 06762, United States
  • GSK Investigational Site
    Coral Gables, Florida 33134, United States
  • GSK Investigational Site
    Miami, Florida 33126, United States
  • GSK Investigational Site
    Miami, Florida 33169, United States
  • GSK Investigational Site
    Augusta, Georgia 30912, United States
  • GSK Investigational Site
    Chicago, Illinois 60637, United States
  • GSK Investigational Site
    Crystal Lake, Illinois 60014, United States
  • GSK Investigational Site
    Fort Wayne, Indiana 46804, United States
  • GSK Investigational Site
    Merrillville, Indiana 46410, United States
  • GSK Investigational Site
    Michigan City, Indiana 46360, United States
  • GSK Investigational Site
    Iowa City, Iowa 52242, United States
  • GSK Investigational Site
    Baton Rouge, Louisiana 70809, United States
  • GSK Investigational Site
    New Orleans, Louisiana 70112, United States
  • GSK Investigational Site
    Baltimore, Maryland 21287, United States
  • GSK Investigational Site
    Jackson, Mississippi 39216, United States
  • GSK Investigational Site
    Kansas City, Missouri 64111, United States
  • GSK Investigational Site
    Saint Louis, Missouri 63110, United States
  • GSK Investigational Site
    Bronx, New York 10461, United States
  • GSK Investigational Site
    Brooklyn, New York 11203, United States
  • GSK Investigational Site
    Buffalo, New York 14215, United States
  • GSK Investigational Site
    Mineola, New York 11501, United States
  • GSK Investigational Site
    New York, New York 10029, United States
  • GSK Investigational Site
    Houston, Texas 77004, United States
  • GSK Investigational Site
    Lufkin, Texas 75904, United States
  • GSK Investigational Site
    San Antonio, Texas 78229, United States
  • GSK Investigational Site
    Hampton, Virginia 23666, United States
  • GSK Investigational Site
    Ciudad Evita, Buenos Aires B1778IFA, Argentina
  • GSK Investigational Site
    La Plata, Buenos Aires B1902COS, Argentina
  • GSK Investigational Site
    Morón, Buenos Aires B1708DPO, Argentina
  • GSK Investigational Site
    Pergamino, Buenos Aires B2700CPM, Argentina
  • GSK Investigational Site
    Pilar, Buenos Aires 1629, Argentina
  • GSK Investigational Site
    Buenos Aires, 1425, Argentina
  • GSK Investigational Site
    Formosa, P3600LLD, Argentina
  • GSK Investigational Site
    Mendoza, M5500AFA, Argentina
  • GSK Investigational Site
    San Miguel de Tucumán, T4000AHL, Argentina
  • GSK Investigational Site
    Adelaide, South Australia 5000, Australia
  • GSK Investigational Site
    Melbourne, Victoria 3004, Australia
  • GSK Investigational Site
    St Albans, Victoria 3021, Australia
  • GSK Investigational Site
    London, Ontario N6A 5A5, Canada
  • GSK Investigational Site
    Toronto, Ontario M3M 0B2, Canada
  • GSK Investigational Site
    Greenfield Park, Quebec J4V 2H1, Canada
  • GSK Investigational Site
    Duesseldorf, Nordrhein-Westfalen 40210, Germany
  • GSK Investigational Site
    Kaiserslautern, Rheinland-Pfalz 67655, Germany
  • GSK Investigational Site
    Wiesbaden, 65191, Germany
  • GSK Investigational Site
    Bangalore, 560055, India
  • GSK Investigational Site
    Chennai, 600037, India
  • GSK Investigational Site
    Delhi, 110076, India
  • GSK Investigational Site
    Gurgaon, 122001, India
  • GSK Investigational Site
    Kozhikode, 673008, India
  • GSK Investigational Site
    New Delhi, 110060, India
  • GSK Investigational Site
    Pune, 411004, India
  • GSK Investigational Site
    Secunderabad, 560020, India
  • GSK Investigational Site
    Thiruvananthapuram, 695011, India
  • GSK Investigational Site
    Genova, Liguria 16132, Italy
  • GSK Investigational Site
    Milano, Lombardia 20153, Italy
  • GSK Investigational Site
    Pavia, Lombardia 27100, Italy
  • GSK Investigational Site
    Cagliari, Sardegna 09100, Italy
  • GSK Investigational Site
    Anyang-Si, Gyeonggi-do, 14068, Korea, Republic of
  • GSK Investigational Site
    Bucheon-si,, 14647, Korea, Republic of
  • GSK Investigational Site
    Incheon, 6510, Korea, Republic of
  • GSK Investigational Site
    Seoul, 05030, Korea, Republic of
  • GSK Investigational Site
    Seoul, 08308, Korea, Republic of
  • GSK Investigational Site
    Suwon, 16499, Korea, Republic of
  • GSK Investigational Site
    Ipoh, 30450, Malaysia
  • GSK Investigational Site
    Kuala Lumpur, 59100, Malaysia
  • GSK Investigational Site
    Penang, 10990, Malaysia
  • GSK Investigational Site
    Torreon, Coahuila 27000, Mexico
  • GSK Investigational Site
    Ciudad De México, Estado De México 14000, Mexico
  • GSK Investigational Site
    Guadalajara., Jalisco 44600, Mexico
  • GSK Investigational Site
    Zapopan, Jalisco 45030, Mexico
  • GSK Investigational Site
    Merida, Yucatán CP 97070, Mexico
  • GSK Investigational Site
    Mérida, Yucatán 97130, Mexico
  • GSK Investigational Site
    Aguascalientes, 20259, Mexico
  • GSK Investigational Site
    Tlalnepantla, 54055, Mexico
  • GSK Investigational Site
    Gdansk, 80-952, Poland
  • GSK Investigational Site
    Kolo, 62-600, Poland
  • GSK Investigational Site
    Krakow, 31-826, Poland
  • GSK Investigational Site
    Lodz, 92-213, Poland
  • GSK Investigational Site
    Lodz, 96-300, Poland
  • GSK Investigational Site
    Ostroda, 14-100, Poland
  • GSK Investigational Site
    Ostroleka, 7410, Poland
  • GSK Investigational Site
    Szczecin, 70-780, Poland
  • GSK Investigational Site
    Irkutsk, 664049, Russian Federation
  • GSK Investigational Site
    Mytishchi, 141007, Russian Federation
  • GSK Investigational Site
    Omsk, 644112, Russian Federation
  • GSK Investigational Site
    Smolensk, 214006, Russian Federation
  • GSK Investigational Site
    St-Petersburg, 197110, Russian Federation
  • GSK Investigational Site
    St. Petersburg, 191104, Russian Federation
  • GSK Investigational Site
    St. Petersburg, 194354, Russian Federation
  • GSK Investigational Site
    St. Petersburg, 196247, Russian Federation

Showing the first 100 of 111 sites across 15 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Natale P, Palmer SC, Jaure A, Hodson EM, Ruospo M, Cooper TE, Hahn D, Saglimbene VM, Craig JC, Strippoli GF. Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease. Cochrane Database Syst Rev. 2022 Aug 25;8(8):CD013751. doi: 10.1002/14651858.CD013751.pub2. PubMed 36005278 ↗
  • Singh AK, Cizman B, Carroll K, McMurray JJV, Perkovic V, Jha V, Johansen KL, Lopes RD, Macdougall IC, Obrador GT, Waikar SS, Wanner C, Wheeler DC, Wiecek A, Stankus N, Strutz F, Blackorby A, Cobitz AR, Meadowcroft AM, Paul G, Ranganathan P, Sedani S, Solomon S. Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients: A Randomized Clinical Trial. JAMA Intern Med. 2022 Jun 1;182(6):592-602. doi: 10.1001/jamainternmed.2022.0605. PubMed 35377393 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2017 to primary completion in Sep 2020, 40 months.

Results were first posted in Oct 2021, 1 year after primary completion.

Of 98 industry-sponsored phase 3 interventional studies under Anemia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 49. This study's 40 months is above that.

Counting every sponsor, half of 150 studies reached it within 30 months; a quarter within 17 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2017
First posted
Jan 24, 2017
StartActual
May 11, 2017
Primary completionActual
Sep 24, 2020
CompletionActual
Sep 24, 2020
Results first posted
Oct 20, 2021
Last update
Oct 20, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 20, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03029208
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jan 24, 2017
Start date
May 11, 2017
Primary completion
Sep 24, 2020
Completion
Sep 24, 2020
Results posted
Oct 20, 2021
Last update
Oct 20, 2021

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GSK1278863

Start the discussion